Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Surrozen, Inc.NASDAQ: SRZN

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock broadly unchanged from a year ago

Common stock stood at $1K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1K+0.0% QoQ
Last fiscal yearDec 2025
$1K— YoY
Year agoMar 2025
$1K+0.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
1K USD
Year-over-year change
—
4-year CAGR
-29.3%

Common Stock vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's Mar 2026 common stock of $1K is the 6th highest of the 8 companies compared; the peer median is $7K.
  • Its year-over-year change of +0.0% is the 6th highest of 7, against a peer median of +42.4%.
  • Common stock amounts to 0.0% of total assets for SRZN, versus a peer median of 0.0%.
SRZN Competitors Peer median
Common Stock for SRZN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AGENAgenus Inc.Mar 2026$385K +44.7%-51.3%0.2%
CGTXCognition Therapeutics, Inc.Mar 2026$90K +45.2%+45.9%0.2%
GLSIGreenwich LifeSciences, Inc.Mar 2026$14.67K +11.2%+3.6%0.1%
IRDOpus Genetics, Inc.Mar 2026$7K +40.0%+51.8%0.0%
IMMXImmix Biopharma, Inc.Mar 2026$5.31K +90.0%+56.0%0.0%
SRZNSurrozen, Inc.Mar 2026$1K +0.0%—0.0%
SEERSeer, Inc.Mar 2026$1K +0.0%+0.0%0.0%
TILInstil Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding SRZN) $7K+42.4%+24.7%0.0%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents33.09M24.69M36.04M34.57M89.25M
Short-term Investments68.76M51.15M000
Net Receivables01.98M2.15M2.54M208K
Inventory00000
Other Current Assets0756K580K671K2.11M
Total Current Assets105.19M81.31M41.13M38.93M91.56M
Property, Plant & Equipment (Net)9.38M6.9M3.86M8.36M6.43M
Goodwill00000
Intangible Assets00000
Long-term Investments21.66M0688K0688K
Tax Assets00000
Other Non-current Assets954K1.23M402K1.17M46K
Total Non-current Assets31.99M8.13M4.95M9.54M7.17M
Total Assets137.17M89.44M46.08M48.47M98.73M
Account Payables2.72M658K525K306K728K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities589K581K292K191K289K
Total Current Liabilities13.57M9.73M7.15M7.32M9.93M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities8.3M326K115K55.89M271.21M
Total Non-current Liabilities13.9M3.7M997K62.53M276.56M
Total Liabilities27.47M13.43M8.15M69.85M286.49M
Common Stock4K0001K
Retained Earnings(142.65M)(178.65M)(221.7M)(285.26M)(527.29M)
Accumulated OCI(119K)(241K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity109.7M76M37.94M(21.38M)(187.76M)
Total Debt7.79M5.6M3.38M8.47M6.64M
Net Debt(25.3M)(19.09M)(32.66M)(26.1M)(82.61M)

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.